PEPFAR funding protection offers “hope” for people living with HIV
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
Post
-
-
UK government targets manufacturing as it eyes £41bn life science sector growth
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector …
-
GSK’s Blenrep US comeback hindered by eye safety concerns
GSK’s plan to bring blood cancer drug Blenrep (belantamab mafodotin) back to markets has hit a stumbling block, after the …
-
Why global 3PL providers are essential to easing supply chain challenges
With tighter budgets, regulatory challenges, and uncertainty from tariffs, pharmaceutical companies are turning to third-party logistics (3PL) suppliers to deliver …
-
Navamedic completes dne pharma acquisition
Oslo, Norway-headquartered Navamedic has completed its previously announced acquisition of dne pharma's business for Nkr225m ($22m). This acquisition comprises dne pharma's …
-
Acumen and JCR partner on brain delivery therapy for Alzheimer’s
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery …
-
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing …
-
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in …
-
Vertex and NHS England agree reimbursement for Alyftrek
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This follows a …
-
LEO Pharma secures rights to Boehringer’s Spevigo for $105m
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening …
-
Health Canada extends Evkeeza approval for children with HoFH
Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) as an adjunct to diet and …
-
WHO endorses Gilead’s Yeztugo for HIV prevention
The World Health Organization (WHO) is recommending the use of Gilead Sciences’ newly approved injectable version of lenacapavir to fight …
-
Scaling smart: how small pharma companies can build resilient supply chains
A robust supply chain is the backbone of stable growth, making it a critical area of concern for small pharma …
-
Illimis secures funding for GAIA-based Alzheimer’s therapeutics
Illimis Therapeutics has completed a Series B funding round, securing $42m to expedite the development of its Gas6-mediated Anti-Inflammatory Adaptor …
-
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) …
